Diabetes
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow Request Permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Avogaro, A.
Right arrow Articles by Cobelli, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Avogaro, A.
Right arrow Articles by Cobelli, C.
Social Bookmarking
 Add to CiteULike   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati  
What's this?

Diabetes, Vol 45, Issue 10 1373-1378, Copyright © 1996 by American Diabetes Association


ARTICLES

Epinephrine exerts opposite effects on peripheral glucose disposal and glucose-stimulated insulin secretion. A stable label intravenous glucose tolerance test minimal model study

A Avogaro, G Toffolo, A Valerio and C Cobelli
Department of Clinical and Experimental Medicine, University of Padova, Italy.

Epinephrine (EPI) plays a pivotal role in regulating glucose metabolism both in splanchnic and peripheral tissues. Nevertheless, previous studies did not clarify the mechanisms by which EPI affect both glucose disposal processes in peripheral tissues and beta-cell secretion. The aim of this study was to investigate, in six normal volunteers, the effects of elevated EPI concentration on peripheral glucose disposal and insulin secretion by using the stable labeled (either [6,6-2H2] or [2-2H1]glucose) intravenous glucose tolerance test (IVGTT) in conjunction with the minimal models of labeled glucose disappearance and C-peptide secretion. Elevated plasma EPI concentration significantly decreased glucose effectiveness (SG*) by 29% (0.0059 +/- 0.0013 vs. 0.0083 +/- 0.0011 min-1, P < 0.05), and even more, 61%, insulin sensitivity (SI*); (22 +/- 6 x 10(4) vs. 54 +/- 20 x 10(4) min-1.pmol.l-1; P < 0.01). These findings are not due to an isotopic effect induced by an enhanced glycogen breakdown, because the [2-2H1]glucose tracer, which is not incorporated into glycogen, gave results similar to those of [6,6-2H2]glucose tracer. No differences were observed in first phase cell sensitivity, phi 1, in the EPI study (199 +/- 91 vs. 245 +/- 144 10(9), NS), but there was a significant increase in the second-phase cell sensitivity to glucose phi 2, (15.2 +/- 1.7 vs. 17.7 +/- 4.4 10(9).min-1, P < 0.05). In conclusion, EPI selectively impairs peripheral glucose metabolism because of its unique ability to simultaneously and independently decrease glucose effectiveness and insulin sensitivity. Furthermore, EPI enhances phi 2, the ratio between the C-peptide amount secreted during the second phase and the area under the curve of the glucose signal, indicating that the observed increase of C-peptide concentration is due not only to the augmented glucose signal but also to a specific EPI-mediated enhancement of beta-cell responsivity to glucose.
Add to CiteULike CiteULike   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati    What's this?


This article has been cited by other articles:


Home page
Am. J. Clin. Nutr.Home page
J. A Greenberg, C. N Boozer, and A. Geliebter
Coffee, diabetes, and weight control.
Am. J. Clinical Nutrition, October 1, 2006; 84(4): 682 - 693.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
A. Brehm, K. Thomaseth, E. Bernroider, P. Nowotny, W. Waldhausl, G. Pacini, and M. Roden
The Role of Endocrine Counterregulation for Estimating Insulin Sensitivity from Intravenous Glucose Tolerance Tests
J. Clin. Endocrinol. Metab., June 1, 2006; 91(6): 2272 - 2278.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
P. Vicini, A. Avogaro, M. E. Spilker, A. Gallo, and C. Cobelli
Epinephrine effects on insulin-glucose dynamics: the labeled IVGTT two-compartment minimal model approach
Am J Physiol Endocrinol Metab, July 1, 2002; 283(1): E78 - E84.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
F. S. L. Thong and T. E. Graham
Caffeine-induced impairment of glucose tolerance is abolished by beta -adrenergic receptor blockade in humans
J Appl Physiol, June 1, 2002; 92(6): 2347 - 2352.
[Abstract] [Full Text] [PDF]


Home page
DiabetesHome page
R. P. Hoffman, C. A. Sinkey, J. M. Dopp, and B. G. Phillips
Systemic and Local Adrenergic Regulation of Muscle Glucose Utilization During Hypoglycemia in Healthy Subjects
Diabetes, March 1, 2002; 51(3): 734 - 742.
[Abstract] [Full Text] [PDF]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
G. Toffolo, E. Breda, M. K. Cavaghan, D. A. Ehrmann, K. S. Polonsky, and C. Cobelli
Quantitative indexes of {beta}-cell function during graded up&down glucose infusion from C-peptide minimal models
Am J Physiol Endocrinol Metab, January 1, 2001; 280(1): E2 - E10.
[Abstract] [Full Text] [PDF]


Home page
J. Clin. Endocrinol. Metab.Home page
J. Walston, K. Silver, H. Hilfiker, R. E. Andersen, M. Seibert, B. Beamer, J. Roth, E. Poehlman, and A. R. Shuldiner
Insulin Response to Glucose Is Lower in Individuals Homozygous for the Arg 64 Variant of the {beta}-3-Adrenergic Receptor
J. Clin. Endocrinol. Metab., November 1, 2000; 85(11): 4019 - 4022.
[Abstract] [Full Text]


Home page
Am. J. Physiol. Endocrinol. Metab.Home page
C. Cobelli, A. Caumo, and M. Omenetto
Minimal model SG overestimation and SI underestimation: improved accuracy by a Bayesian two-compartment model
Am J Physiol Endocrinol Metab, September 1, 1999; 277(3): E481 - E488.
[Abstract] [Full Text] [PDF]


Home page
J. Appl. Physiol.Home page
M. C. Lekas, S. J. Fisher, B. El-Bahrani, M. van Delangeryt, M. Vranic, and Z. Q. Shi
Glucose uptake during centrally induced stress is insulin independent and enhanced by adrenergic blockade
J Appl Physiol, August 1, 1999; 87(2): 722 - 731.
[Abstract] [Full Text] [PDF]




HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Diabetes Diabetes Care Clinical Diabetes Diabetes Spectrum
Copyright © 1996 by the American Diabetes Association.